### **Overview** Piramal Pharma Limited (PPL) is a globally diversified pharmaceutical company headquartered in Mumbai, India. It was formed as an independent, publicly listed entity in October 2022 through the demerger from Piramal Enterprises Limited, consolidating its pharma operations into a focused, scalable organization. Listed on the BSE and NSE, PPL operates through three core business verticals and serves customers across **over 100 countries**, exporting approximately **68.6% of its turnover**. With a strategic investment from The Carlyle Group (20% stake in 2020), PPL has pursued a focused growth strategy leveraging its strengths in complex manufacturing, vertical integration, and consumer engagement. --- ### **Core Business Segments** #### **1. Piramal Pharma Solutions (PPS)** – *Global Contract Development and Manufacturing Organization (CDMO)* PPS is a leading end-to-end CDMO offering integrated services across drug discovery, clinical development, and commercial manufacturing of active pharmaceutical ingredients (APIs) and finished formulations. - **Capabilities:** Specialized expertise in high-potency APIs (HPAPIs), peptides, antibody-drug conjugates (ADCs), sterile injectables (liquid and lyophilized), hormonal oral solids, complex generics, and on-patent molecules. - **Bioscience Expansion:** Strategic 33.33% minority stake in **Yapan Bio**, enhancing capabilities in biologics, vaccines, and biotherapeutics. Yapan also contributes monoclonal antibodies (mAbs) to ADC programs. - **Global Facilities:** Operates **17 advanced manufacturing and development sites** in India, the U.S., Canada, the U.K., and Europe. Key hubs include: - **Grangemouth, UK:** World’s first USFDA-approved commercial ADC site with end-to-end conjugation, linker, and fill-finish. - **Lexington, KY (USA):** Expansion underway to more than double sterile fill/finish capacity by 2027 (investment: $90M). - **Sellersville, PA:** Dedicated oral solid dosage (OSD) suite for fixed-dose combinations (FDCs), developed in partnership with NewAmsterdam Pharma for its investigational cholesterol drug. - **Riverview, MI:** High-tech HPAPI and payload-linker manufacturing; receiving $90M expansion to add commercial-scale capabilities. - **Key Collaborations:** Partnership with **NewAmsterdam Pharma** and **Menarini Group**. - **Client Base:** Serves over **500 clients**, including global innovator pharma, emerging biotechs, and generics firms. - **Commercial Success:** - **85% of CDMO revenues** come from highly regulated markets (U.S., EU, Japan). - **$179 million** earned from commercial manufacturing of **18 on-patent molecules** in FY2025 (up from $19M in FY2019). - **54% of revenue** derived from innovation-driven projects, growing at a **21% CAGR**. - **Growth Targets:** Aims to scale CDMO revenues to **$1.2 billion by FY2030**, with a target EBITDA margin of **~25%**. --- #### **2. Piramal Critical Care (PCC)** – *Complex Hospital Generics (CHG)* PCC is a global leader in hospital-focused injectables and inhalation anesthetics, with a strong presence in U.S. and European markets. - **Key Products:** Sevoflurane, Desflurane, Isoflurane, Fentanyl, Gablofen (Baclofen), Mitigo, and newer entrants like **Neoatricon®**, a pediatric dopamine formulation. - **Market Leadership:** - **U.S. #1 in Sevoflurane** (44% value share), **Baclofen pre-filled syringes/vials** (75% share), and **Fentanyl (ampoules)** in Japan, South Africa, Indonesia, and Saudi Arabia. - **Global #4 in inhalation anesthesia** by value. - **Supply Chain Mastery:** Fully **vertically integrated** across: - **Dahej, India:** Manufactures key starting materials (KSMs) and fluorochemicals – now expanded to support global demand. - **Digwal, India:** Produces Sevoflurane and Isoflurane – new production lines added. - **Bethlehem, PA, USA:** Manufactures Sevoflurane and Desflurane – FDA-compliant. - **Global Reach:** Products used in **6,000+ hospitals, surgical centers, and veterinary clinics** globally. Direct sales in the **U.S., UK, Germany, France, and Italy**; partnerships elsewhere. - **New Products & Approvals:** - **Neoatricon®** approved in UK, Germany, France, Italy, and Norway (developed via partnership with **BrePco Biopharma**) – only pre-diluted, age-appropriate dopamine formulation for neonates/children. - Expansion of injectable product pipeline: **145 molecules in development**, with **31 in Phase III**. - **Growth Strategy:** - Focus on **505(b)(2) applications**, differentiated and complex generics, with ~30 molecules expected to lose exclusivity in U.S./EU in the next five years. - **$600 million revenue target by FY2030**, with **25%+ EBITDA margin**. - **Challenges:** Growth previously constrained by third-party CMO supply bottlenecks; now improving with internal capacity expansion and vendor diversification. --- #### **3. Piramal Consumer Healthcare (PCH)** – *India OTC and Wellness Brand Platform* PCH is a brand-led, asset-light OTC business focused on skincare, kids' wellness, women’s health, digestion, and hygiene. - **Portfolio:** Offers **30+ OTC brands**, including: - **Power Brands** (49% of PCH revenue): **Lacto Calamine, Little’s, i-range, CIR, Polycrol, Tetmosol**. - **Bayer Distribution Agreement:** For brands like **Saridon, Supradyn, Becozym, Benadon**. - **Distribution Network:** - **180,000+ chemists, cosmetics, and gift shops**. - **8,000–13,000 modern trade outlets**. - **20+ e-commerce platforms** (e.g., PharmEasy, Netmeds, Amazon). - **Direct-to-Consumer (D2C):** Own platform **Wellify.in**, processing **130,000+ orders/month**. - **Digital & E-commerce Strategy:** - **E-commerce now contributes 21% of PCH revenue**, growing at a **~39% YoY rate** and **47% CAGR over four years**. - Used as a **testbed** for new product launches. - Focus on **optimal pricing**, platform efficiency, and expanding into **quick commerce**. - **Growth & Innovation:** - Launched **21 new products and 31 new SKUs in FY25** (~200+ in the past four years). - New launches contribute **8% of PCH sales**. - R&D focus on **alternative delivery systems, formulation enhancements, and digital consumer insights**. - **Leadership:** **Mr. Sai Ramana Ponugoti** (ex-P&G) leads as CEO, driving omni-channel expansion. - **Revenue & Targets:** - Crossed **₹1,000 crore** in annual revenue (FY2025). - Aiming for **$200 million revenue (~₹1,500–1,700 crore) by FY2030** with **double-digit EBITDA margins**. --- ### **Strategic Investments & Capacity Expansion** - **$90 million investment:** Expands sterile fill-finish in **Lexington, KY**, and payload-linker capacity in **Riverview, MI** – supports ADCelerate™ program. - **$570 million invested in U.S. capabilities** (as of May 2025), including: - Brownfield expansions at **Sellersville** (OSD) and **Bethlehem** (inhalation anesthesia). - **$90 million brownfield expansion** in Lexington to add **24,000 sq. ft.**, new filling lines, lyophilizers, and lab automation. - **£45 million investment** in **Grangemouth** (UK), increasing ADC capacity by **70–80%**; operational in FY2024. - **India Expansion:** Increased KSM output at **Dahej**, and new Sevoflurane lines at **Digwal** – to capture **$400 million** emerging market opportunity. - **Catalyst NxGen:** Major **ERP transformation program** underway, with phased rollout from FY2025–2026, to digitize and standardize global operations. --- ### **Strategic Alliances & JV Interests** - **Yapan Bio (33.33% stake):** Biologics, vaccines, and gene therapy CDMO based in Hyderabad. Critical to long-term biologics and ADC pipeline. - **AbbVie Therapeutics India (formerly Allergan India):** - Piramal holds a **49% stake** (was 51% previously). - **Market leader in ophthalmology** in India – brands like **Refresh Tears, Lumigan, Combigan, Pred Forte**. - Reported **₹461 crore revenue in FY2024** (unaudited), with 27% PAT margin. - **BrePco Biopharma Partnership:** Commercialization rights to **Neoatricon®**, a breakthrough product in **paediatric cardiovascular care**. - **Bayer Pharmaceuticals:** Distribution and manufacturing agreement for **four key brands**. --- ### **Financial & Operational Highlights** | Metric | FY2025 | |-------|--------| | **Revenue Contribution (PPS/CHG/PCH)** | 59% / 29% / 12% | | **Exports** | 68.55% of total turnover | | **CDMO Revenue** | Driven by innovation (54%) and regulated markets (85%) | | **CHG Revenue** | ₹2,633 crore (8% YoY growth), led by volume in inhalation anesthesia | | **PCH Revenue** | ₹1,093 crore (double-digit growth), EBITDA recovery in e-commerce | | **PPL Workforce** | ~6,700 employees globally | | **Regulatory Record** | **Zero OAI (Official Action Indicated)** from USFDA since FY12 |